MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-GA-01-0002961
Market Cap
₹31.88 Cr
SANDUPHQ · BSE
Share Price
₹33.99
+3.00% today
Revenue
₹67.19 Cr
FY 2024-25 · -0.1% YoY
EBITDA
₹2.77 Cr
Margin 4.1%
Net Profit
₹1.56 Cr
FY 2024-25 · +6.1% YoY
P/E (TTM)
21.5x
P/B 1.0x
ROE
4.7%
ROCE 6.9%
Authorised capital
₹10 Cr
Registered with MCA
About Sandu Pharmaceuticals Limited
Data last updated:
Sandu Pharmaceuticals Limited is a public limited company based in Goa, India. It operates in the ayurvedic products and services segment of the healthcare sector. It was incorporated on 15 November 1985 and has been in existence for over 41 years.
The company is registered with the Registrar of Companies (ROC), Goa, under CIN L24233GA1985PLC001587. Its GSTIN is 30AAACS6291G1ZK (Goa). The company holds 6 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524703.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹9.66 Cr. It was formerly known as Sandu Pharmaceuticals Private Limited and Samartha Sandu Pharmaceuticals Private Limited. It is led by directors including Shashank Bhaskar Sandu and Jayshree Bhasker Sandu.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No.25 26 29 & 30 Pilerne Industrial Estate Marra Bardez Goa – 403 511., Goa, India.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹69.93 Cr, a growth of 4.1% compared to the previous year. For the same year it recorded a net profit of ₹1.75 Cr (net margin 2.5%) and EBITDA of ₹2.99 Cr (EBITDA margin 4.3%). The net worth stands at ₹43.67 Cr (up 3.9% YoY). Total assets are valued at ₹44.09 Cr (up 3.8% YoY).
The company has about 295 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 2 brands: NaattuMarundhuKadai and Sandu Pharmaceuticals. As per MCA filings, the company has satisfied charges of ₹53.06 Cr on record. Court records list 26 cases involving the company, including 3 filed by the company and 23 filed against it. The company has 18 deals on record (17 market trades, 1 funding round), with disclosed funding of ₹1.84 Cr; the latest was in March 2024. Its 7 peer companies in the Healthcare industry (Ayurvedic Products and Services, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Prakruti Products Private Limited with revenue of ₹69.57 Cr. The company has 13 MSME Form 1 returns on record between 2019 and 2024, listing 690 overdue payments to 33 micro and small suppliers.
Sandu Pharmaceuticals Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GA-01-0002961). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sandu.in.
Company details
CIN L24233GA1985PLC001587
Registration Number 001587
Incorporation Date 15 November 1985
ROC Goa
Listing Status Listed - Listed on BSE (524703)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GA-01-0002961
Name history
Sandu Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Sandu Pharmaceuticals Private Limited, and Samartha Sandu Pharmaceuticals Private Limited. The current legal name is Sandu Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| Sandu Pharmaceuticals Limited | Current |
| Sandu Pharmaceuticals Private Limited | Previous |
| Samartha Sandu Pharmaceuticals Private Limited | Previous |
Key People
Shashank Bhaskar Sandu Director Jayshree Bhasker Sandu Director Vijay Kottapalli Director Recognitions & Rankings of Sandu Pharmaceuticals
Contact details
Sandu Pharmaceuticals Limited's registered office is in Goa. Its website is sandu.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.25 26 29 & 30 Pilerne Industrial Estate Marra Bardez Goa – 403 511., Goa, India
- IndustryHealthcare, Ayurvedic Products & Services
To see the full contact details of Sandu Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Sandu Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Sandu Pharmaceuticals operates two associated brands: NaattuMarundhuKadai and Sandu Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Online retailer of herbal medicines, Ayurvedic products, and health supplements. | naattumarundhukadai.com | |
| Ayurvedic health and wellness products are manufactured in India. | sandu.in |
Business activity
The main business activity of Sandu Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Sandu Pharmaceuticals Limited, buy the company report.
Financials of Sandu Pharmaceuticals Limited
FY 2025-26 filings availableSandu Pharmaceuticals Limited reported revenue of ₹69.93 Cr (up 4.1% YoY) for FY 2025-26.
Financial Highlights
FY 2024-25 · ConsolidatedRevenue
₹67.19 Cr
-0.1% YoY
EBITDA
₹2.77 Cr
+20.4% YoY
Profit After Tax
₹1.56 Cr
+6.1% YoY
Net Worth
₹42.02 Cr
+3.5% YoY
Total Assets
₹42.44 Cr
+4.4% YoY
Total Debt
Nil
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Income statement | |||
| Revenue | 67.19 | 67.28 | 65.35 |
| Revenue growth | -0.1% | +3.0% | - |
| EBITDA | 2.77 | 2.30 | 2.48 |
| EBITDA margin | +4.1% | +3.4% | +3.8% |
| Profit before tax | 2.17 | 2.08 | 2.21 |
| Net profit | 1.56 | 1.47 | 1.52 |
| Net profit margin | +2.3% | +2.2% | +2.3% |
| EPS (₹) | 1.61 | 1.51 | 1.57 |
| Balance sheet | |||
| Total assets | 42.44 | 40.65 | 39.24 |
| Net worth | 42.02 | 40.59 | 39.24 |
| Total debt | 0.00 | 0.00 | 0.00 |
| Cash & bank | 2.65 | 1.21 | 2.30 |
| Net working capital | 14.22 | 11.67 | 11.66 |
| Cash flow | |||
| Cash from operations | 0.95 | 0.76 | 0.22 |
| Cash from investing | (0.19) | (1.31) | 0.54 |
| Cash from financing | (0.46) | (0.72) | 0.58 |
| Particulars | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.07 | 18.37 | 17.70 | 17.05 | 15.60 | 17.43 | 16.61 | 17.66 |
| Revenue growth (YoY) | -9.8% | +5.4% | +6.6% | -3.5% | +2.2% | - | - | - |
| Other income | 0.07 | 0.02 | 0.03 | 0.04 | 0.31 | 0.03 | 0.09 | 0.00 |
| EBITDA | 0.45 | 0.99 | 0.91 | 0.41 | 0.61 | 0.51 | 0.83 | 0.36 |
| EBITDA margin | +3.2% | +5.4% | +5.1% | +2.4% | +3.9% | +2.9% | +5.0% | +2.0% |
| Depreciation | 0.15 | 0.19 | 0.17 | 0.16 | 0.19 | 0.14 | 0.13 | 0.12 |
| Interest | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
| Profit before tax | 0.34 | 0.79 | 0.74 | 0.27 | 0.72 | 0.38 | 0.78 | 0.22 |
| Tax | 0.01 | 0.24 | 0.24 | 0.11 | 0.12 | 0.17 | 0.21 | 0.10 |
| Net profit | 0.33 | 0.55 | 0.50 | 0.16 | 0.60 | 0.21 | 0.57 | 0.12 |
| EPS (₹) | 0.34 | 0.57 | 1.95 | 0.17 | 0.62 | 0.21 | 0.57 | 0.11 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 69.93 | 67.19 | 67.28 | 65.35 | 65.50 | 58.76 | 48.37 |
| Revenue growth | +4.1% | -0.1% | +3.0% | -0.2% | +11.5% | +21.5% | - |
| EBITDA | 2.99 | 2.76 | 2.30 | 2.48 | 2.88 | 2.15 | 1.45 |
| EBITDA margin | +4.3% | +4.1% | +3.4% | +3.8% | +4.4% | +3.7% | +3.0% |
| Profit before tax | 2.64 | 2.16 | 2.08 | 2.21 | 2.32 | 1.67 | 0.92 |
| Net profit | 1.75 | 1.55 | 1.47 | 1.52 | 1.59 | 1.08 | 0.72 |
| Net profit margin | +2.5% | +2.3% | +2.2% | +2.3% | +2.4% | +1.8% | +1.5% |
| EPS (₹) | 1.83 | 1.60 | 1.51 | 1.58 | 1.80 | 1.38 | 1.02 |
| Balance sheet | |||||||
| Total assets | 44.09 | 42.49 | 40.66 | 39.24 | 36.47 | 33.51 | 30.48 |
| Net worth | 43.67 | 42.02 | 40.59 | 39.24 | 36.47 | 33.49 | 29.24 |
| Total debt | 0.11 | 0.06 | 0.00 | 0.00 | 0.00 | 0.02 | 1.25 |
| Cash & bank | 6.86 | 2.65 | 1.20 | 2.29 | 4.17 | 11.66 | 1.54 |
| Net working capital | 15.01 | 14.27 | 11.66 | 11.66 | 11.77 | 18.05 | 12.32 |
| Cash flow | |||||||
| Cash from operations | 6.12 | 0.95 | 0.76 | 0.22 | 0.95 | 7.59 | 6.20 |
| Cash from investing | (0.57) | (0.18) | (1.31) | 0.53 | (5.47) | (5.58) | (0.37) |
| Cash from financing | (0.94) | (0.46) | (0.72) | 0.58 | 0.93 | 1.30 | (5.36) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.39 | 16.85 | 18.76 | 17.62 | 16.70 | 14.07 | 18.37 | 17.70 |
| Revenue growth (YoY) | -1.9% | +19.8% | +2.1% | -0.5% | -2.1% | - | - | - |
| Other income | 0.02 | 0.37 | 0.01 | 0.05 | 0.02 | 0.07 | 0.02 | 0.03 |
| Total expenses | 15.85 | 16.28 | 17.72 | 16.76 | 16.17 | 13.62 | 17.38 | 16.79 |
| EBITDA | 0.54 | 0.57 | 1.04 | 0.86 | 0.53 | 0.45 | 0.99 | 0.91 |
| EBITDA margin | +3.3% | +3.4% | +5.5% | +4.9% | +3.2% | +3.2% | +5.4% | +5.1% |
| Depreciation | 0.16 | 0.16 | 0.17 | 0.17 | 0.18 | 0.15 | 0.19 | 0.17 |
| Interest | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | 0.37 | 0.75 | 0.85 | 0.71 | 0.34 | 0.34 | 0.79 | 0.74 |
| Tax | 0.13 | 0.70 | (0.12) | 0.19 | 0.12 | 0.01 | 0.24 | 0.24 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.07 | 18.37 | 17.70 | 17.05 | 15.60 | 17.43 | 16.61 | 17.66 |
| Revenue growth (YoY) | -9.8% | +5.4% | +6.6% | -3.5% | +2.2% | - | - | - |
| Other income | 0.07 | 0.02 | 0.03 | 0.04 | 0.31 | 0.03 | 0.09 | 0.00 |
| EBITDA | 0.45 | 0.99 | 0.91 | 0.41 | 0.61 | 0.51 | 0.83 | 0.36 |
| EBITDA margin | +3.2% | +5.4% | +5.1% | +2.4% | +3.9% | +2.9% | +5.0% | +2.0% |
| Depreciation | 0.15 | 0.19 | 0.17 | 0.16 | 0.19 | 0.14 | 0.13 | 0.12 |
| Interest | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
| Profit before tax | 0.34 | 0.79 | 0.74 | 0.27 | 0.72 | 0.38 | 0.78 | 0.22 |
| Tax | 0.01 | 0.24 | 0.24 | 0.11 | 0.12 | 0.17 | 0.21 | 0.10 |
| Net profit | 0.33 | 0.55 | 0.50 | 0.16 | 0.60 | 0.21 | 0.57 | 0.12 |
| EPS (₹) | 0.34 | 0.57 | 1.95 | 0.17 | 0.62 | 0.21 | 0.57 | 0.11 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Revenue | 67.19 | 67.28 | 65.35 |
| Revenue growth | -0.1% | +3.0% | - |
| Other income | 0.17 | 0.42 | 0.33 |
| Total expenses | 64.42 | 64.98 | 62.87 |
| Employee cost | 10.92 | 10.07 | 11.10 |
| EBITDA | 2.77 | 2.30 | 2.48 |
| EBITDA margin | +4.1% | +3.4% | +3.8% |
| Depreciation | 0.67 | 0.58 | 0.52 |
| Interest | 0.10 | 0.06 | 0.08 |
| Profit before tax | 2.17 | 2.08 | 2.21 |
| Tax | 0.61 | 0.61 | 0.69 |
| Net profit | 1.56 | 1.47 | 1.52 |
| Net profit margin | +2.3% | +2.2% | +2.3% |
| EPS (₹) | 1.61 | 1.51 | 1.57 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 9.66 | 9.66 | 9.66 |
| Reserves & surplus | 32.36 | 30.93 | 29.58 |
| Shareholders' funds (net worth) | 42.02 | 40.59 | 39.24 |
| Minority interest | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 |
| Total liabilities | 42.44 | 40.65 | 39.24 |
| Assets | |||
| Gross block | 30.29 | 29.35 | 27.51 |
| Net block | 18.15 | 17.88 | 16.62 |
| Capital work in progress | 0.00 | 0.00 | 0.42 |
| Investments | 11.22 | 10.42 | 9.65 |
| Inventories | 14.15 | 12.25 | 14.33 |
| Sundry debtors | 4.76 | 4.87 | 4.79 |
| Cash & bank balances | 2.65 | 1.21 | 2.30 |
| Loans & advances | 4.74 | 3.98 | 4.13 |
| Total current assets | 26.30 | 22.31 | 25.55 |
| Total current liabilities | 12.08 | 10.64 | 13.89 |
| Net working capital | 14.22 | 11.67 | 11.66 |
| Total assets | 42.44 | 40.65 | 39.24 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Opening cash | 1.00 | 2.28 | 0.94 |
| Net cash from operating activities | 0.95 | 0.76 | 0.22 |
| Net cash from investing activities | (0.19) | (1.31) | 0.54 |
| Net cash from financing activities | (0.46) | (0.72) | 0.58 |
| Net change in cash | 0.30 | (1.27) | 1.34 |
| Closing cash | 2.65 | 1.21 | 2.30 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Growth | |||
| Sales growth | -0.1% | +3.0% | - |
| EBITDA growth | +20.4% | -7.3% | - |
| PBT growth | +4.3% | -5.9% | +9997.0% |
| Net income growth | +6.1% | -3.3% | - |
| Profitability & leverage | |||
| Net income margin | +2.3% | +2.2% | +2.3% |
| Return on capital employed | +6.9% | +6.0% | +5.9% |
| Return on net worth | +4.7% | +4.1% | +3.9% |
| Debt / equity | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 |
| Interest cover | 4.76 | 3.49 | 4.08 |
| Efficiency & per share | |||
| Fixed asset turnover | 3.17 | 2.79 | 2.38 |
| Inventory turnover | 5.09 | 5.06 | 4.56 |
| Debtors turnover | 13.95 | 13.93 | 13.64 |
| EPS (₹) | 1.61 | 1.51 | 1.57 |
| Dividend per share (₹) | 0.80 | 0.80 | 0.00 |
| Book value per share (₹) | 34.63 | 33.01 | 40.62 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.39 | 16.85 | 18.76 | 17.62 | 16.70 | 14.07 | 18.37 | 17.70 |
| Revenue growth (YoY) | -1.9% | +19.8% | +2.1% | -0.5% | -2.1% | - | - | - |
| Other income | 0.02 | 0.37 | 0.01 | 0.05 | 0.02 | 0.07 | 0.02 | 0.03 |
| Total expenses | 15.85 | 16.28 | 17.72 | 16.76 | 16.17 | 13.62 | 17.38 | 16.79 |
| EBITDA | 0.54 | 0.57 | 1.04 | 0.86 | 0.53 | 0.45 | 0.99 | 0.91 |
| EBITDA margin | +3.3% | +3.4% | +5.5% | +4.9% | +3.2% | +3.2% | +5.4% | +5.1% |
| Depreciation | 0.16 | 0.16 | 0.17 | 0.17 | 0.18 | 0.15 | 0.19 | 0.17 |
| Interest | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | 0.37 | 0.75 | 0.85 | 0.71 | 0.34 | 0.34 | 0.79 | 0.74 |
| Tax | 0.13 | 0.70 | (0.12) | 0.19 | 0.12 | 0.01 | 0.24 | 0.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 69.93 | 67.19 | 67.28 | 65.35 | 65.50 | 58.76 | 48.37 |
| Revenue growth | +4.1% | -0.1% | +3.0% | -0.2% | +11.5% | +21.5% | - |
| Other income | 0.44 | 0.17 | 0.42 | 0.33 | 0.08 | 0.19 | 0.45 |
| Total expenses | 66.94 | 64.43 | 64.98 | 62.87 | 62.62 | 56.61 | 46.92 |
| Employee cost | 10.69 | 10.92 | 10.07 | 11.10 | 8.91 | 8.02 | 6.85 |
| EBITDA | 2.99 | 2.76 | 2.30 | 2.48 | 2.88 | 2.15 | 1.45 |
| EBITDA margin | +4.3% | +4.1% | +3.4% | +3.8% | +4.4% | +3.7% | +3.0% |
| Depreciation | 0.68 | 0.67 | 0.58 | 0.52 | 0.53 | 0.56 | 0.55 |
| Interest | 0.11 | 0.10 | 0.06 | 0.08 | 0.11 | 0.11 | 0.43 |
| Profit before tax | 2.64 | 2.16 | 2.08 | 2.21 | 2.32 | 1.67 | 0.92 |
| Tax | 0.89 | 0.61 | 0.61 | 0.69 | 0.73 | 0.59 | 0.20 |
| Net profit | 1.75 | 1.55 | 1.47 | 1.52 | 1.59 | 1.08 | 0.72 |
| Net profit margin | +2.5% | +2.3% | +2.2% | +2.3% | +2.4% | +1.8% | +1.5% |
| EPS (₹) | 1.83 | 1.60 | 1.51 | 1.58 | 1.80 | 1.38 | 1.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.66 | 9.66 | 9.66 | 9.66 | 8.81 | 7.92 | 7.08 |
| Reserves & surplus | 34.01 | 32.36 | 30.93 | 29.58 | 27.22 | 24.67 | 22.16 |
| Shareholders' funds (net worth) | 43.67 | 42.02 | 40.59 | 39.24 | 36.47 | 33.49 | 29.24 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 1.25 |
| Unsecured loans | 0.11 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.11 | 0.06 | 0.00 | 0.00 | 0.00 | 0.02 | 1.25 |
| Total liabilities | 44.09 | 42.49 | 40.66 | 39.24 | 36.47 | 33.51 | 30.48 |
| Assets | |||||||
| Gross block | 30.96 | 30.29 | 29.35 | 27.51 | 26.38 | 26.02 | 25.89 |
| Net block | 18.12 | 18.15 | 17.88 | 16.62 | 16.01 | 16.18 | 16.60 |
| Capital work in progress | 0.06 | 0.00 | 0.00 | 0.42 | 0.48 | 0.00 | 0.00 |
| Investments | 12.30 | 11.22 | 10.43 | 9.66 | 9.11 | 0.24 | 0.82 |
| Inventories | 10.47 | 14.15 | 12.25 | 14.33 | 11.27 | 11.14 | 14.36 |
| Sundry debtors | 5.41 | 4.76 | 4.87 | 4.79 | 3.99 | 5.35 | 4.68 |
| Cash & bank balances | 6.86 | 2.65 | 1.20 | 2.29 | 4.17 | 11.66 | 1.54 |
| Loans & advances | 2.59 | 4.74 | 3.98 | 4.13 | 4.21 | 2.40 | 1.83 |
| Total current assets | 25.33 | 26.30 | 22.30 | 25.54 | 23.64 | 30.55 | 22.41 |
| Total current liabilities | 10.32 | 12.03 | 10.64 | 13.88 | 11.87 | 12.50 | 10.09 |
| Net working capital | 15.01 | 14.27 | 11.66 | 11.66 | 11.77 | 18.05 | 12.32 |
| Total assets | 44.09 | 42.49 | 40.66 | 39.24 | 36.47 | 33.51 | 30.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.30 | 1.00 | 2.27 | 0.94 | 4.53 | 1.22 | 0.74 |
| Net cash from operating activities | 6.12 | 0.95 | 0.76 | 0.22 | 0.95 | 7.59 | 6.20 |
| Net cash from investing activities | (0.57) | (0.18) | (1.31) | 0.53 | (5.47) | (5.58) | (0.37) |
| Net cash from financing activities | (0.94) | (0.46) | (0.72) | 0.58 | 0.93 | 1.30 | (5.36) |
| Net change in cash | 4.60 | 0.31 | (1.27) | 1.33 | (3.59) | 3.31 | 0.48 |
| Closing cash | 6.86 | 2.65 | 1.20 | 2.29 | 4.17 | 11.66 | 1.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +4.1% | -0.1% | +3.0% | -0.2% | +11.5% | +21.5% | - |
| EBITDA growth | +8.3% | +20.0% | -7.3% | -13.9% | +34.0% | +48.3% | - |
| PBT growth | +22.2% | +3.9% | -5.9% | -4.7% | +38.9% | +81.5% | -8.0% |
| Net income growth | +12.9% | +5.4% | -3.3% | -4.4% | +47.2% | +50.0% | - |
| Revenue CAGR (3Y) | +2.3% | +0.9% | +4.6% | +10.6% | +9.8% | +6.2% | +4.2% |
| EBITDA CAGR (3Y) | +6.4% | -1.4% | +2.3% | +19.6% | +11.5% | -4.4% | -7.8% |
| Profitability & leverage | |||||||
| Net income margin | +2.5% | +2.3% | +2.2% | +2.3% | +2.4% | +1.8% | +1.5% |
| Return on capital employed | +8.0% | +6.9% | +6.0% | +6.9% | +9.4% | +7.9% | +4.8% |
| Return on net worth | +5.2% | +4.7% | +4.1% | +4.6% | +6.1% | +4.9% | +3.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.15 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 4.76 | 4.78 | 3.49 | 4.08 | 4.68 | 6.92 | 47.78 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.16 | 3.17 | 2.79 | 2.91 | 3.82 | 3.50 | 2.28 |
| Inventory turnover | 5.68 | 5.09 | 5.06 | 5.11 | 5.85 | 4.61 | 3.50 |
| Debtors turnover | 13.75 | 13.95 | 13.93 | 14.89 | 14.03 | 11.72 | 10.20 |
| EPS (₹) | 1.83 | 1.60 | 1.51 | 1.58 | 1.80 | 1.38 | 1.02 |
| Dividend per share (₹) | 0.00 | 0.80 | 0.80 | 0.00 | 0.75 | 0.50 | 0.00 |
| Book value per share (₹) | 36.48 | 34.62 | 33.01 | 40.62 | 30.71 | 29.63 | 28.22 |
To see the full year-wise statements and ratios of Sandu Pharmaceuticals Limited, buy the company report.
Board of directors of Sandu Pharmaceuticals Limited
Sandu Pharmaceuticals has 5 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shashank Bhaskar Sandu | Director | 01 Jun 2011 | 15 Years 4 Months | Current |
| Jayshree Bhasker Sandu | Director | 30 Sep 2024 | 2 Years 0 Months | Current |
| Vijay Kottapalli | Director | 12 Aug 2024 | 2 Years 2 Months | Current |
| Balram Viswanathan | Director | 14 Aug 2023 | 3 Years 2 Months | Current |
| Ajit Rajaram Kantak | Director | 14 Aug 2023 | 3 Years 2 Months | Current |
Peer comparison
Sandu Pharmaceuticals Limited is compared with the 7 companies closest to it by revenue in the Healthcare industry (Ayurvedic Products and Services, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sandu Pharmaceuticals Limitedthis company | ₹69.93 Cr (FY 2026) | ₹1.75 Cr | 2.5% | 4.1% | 295 | Goa, India |
| Prakruti Products Private Limited | ₹69.57 Cr (FY 2024) | 13.0% | Karantaka, Karnataka, India | |||
| Kumaon Exports Private Limited | ₹68.75 Cr (FY 2025) | 8.0% | Dehradun, Uttarakhand, India | |||
| KRM Ayurveda Limited | ₹67.57 Cr (FY 2024) | -24.0% | Delhi, India | |||
| Satyadivis Pharmaceuticals Private Limited | ₹67.35 Cr (FY 2024) | 2.0% | Jinnaram, Telangana, India | |||
| Africure Pharmaceuticals (India) Private Limited | ₹66.93 Cr (FY 2025) | 1.0% | Palghar, Maharashtra, India | |||
| Swefn Pharmaceuticals Private Limited | ₹66.63 Cr (FY 2025) | 9.0% | Moraiya, Gujarat, India | |||
| Skyec Drugs and Pharmaceuticals Private Limited | ₹66.27 Cr (FY 2025) | 19.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Sandu Pharmaceuticals Limited, buy the company report.
Auditor
Sandu Pharmaceuticals Limited is audited by Dileep & Prithvi for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Dileep & Prithvi | FY 2023 | 122290W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 37.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 62.20%.
Mar 2026
QUARTER
37.80% Promoters
62.20% Retail & Others
Promoter holding - history
Now 37.80% · Mar 2026High 42.90% · Jun 2025Low 37.80% · Dec 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 37.80% | 37.80% | 42.90% | 42.90% |
| Public | 62.20% | 62.20% | 57.10% | 57.10% |
Charges & borrowings
Open charges
None
Satisfied charges
₹53.06 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 09 Jul 2021 | 100461391 | Hdfc Bank Limited | ₹18 Cr | Satisfied | |
| 24 Sep 2018 | 100210389 | Axis Bank Limited | ₹14.75 Cr | Satisfied | |
| 12 Apr 2011 | 10282947 | Dena Bank | ₹1.91 Cr | Satisfied | |
| 21 Dec 2010 | 10265365 | Dena Bank | ₹10 Cr | Satisfied | |
| 30 Apr 2008 | 10110288 | Axis Bank Limited | ₹2.5 Cr | Satisfied |
To see the full charge records of Sandu Pharmaceuticals Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Sandu Pharmaceuticals Limited has 18 deals on record (17 market trades, 1 funding round), with disclosed funding of ₹1.84 Cr; the latest was in March 2024.
Total deals
18
Market trades
17
Funding round
1
Disclosed funding
₹1.84 Cr
Deals on record (5 of 18)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Market trade | ₹59.2 Lakh | Buyer: Trans Scan Securities Private Limited Seller: DPS Tradelink Private Limited |
| Mar 2022 | Funding round | ₹1.84 Cr | Investors: Akshath Finvest and Properties Private Limited , Neelambar Leasing and Finvest Private Limited , 2 individuals |
| Jul 2021 | Market trade | ₹22.6 Lakh | Seller: an individual |
| Mar 2009 | Market trade | ₹7 Lakh | Buyer: an individual Seller: an individual |
| Mar 2009 | Market trade | ₹7.1 Lakh | Buyer: an individual |
To see the full deal history of Sandu Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Sandu Pharmaceuticals Limited has 26 court cases on record: 3 filed by Sandu Pharmaceuticals, 23 filed against it. All cases are disposed.
Total cases
26
Filed by the company
3
Filed against the company
23
Disposed
26
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 18 | 17 | 0 |
| High courts | 8 | 6 | 0 |
Cases on record (5 of 26)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, North Goa, Goa | Court case (RCA) | Filed against the company by an individual | Disposed |
| Bombay High Court | Tax appeal | Filed against the company by PR. Commissioner of Income Tax -14 | Disposed |
| Bombay High Court | Appeal | Filed against the company by Deccan Queen Transport Company, THR. Its Aut. Attorney, Gajanan Uske., | Disposed |
| Bombay High Court | Appeal | Filed against the company by Deccan Queen Transport Company, THR. Its Aut. Attorney, Gajanan Uske., | Disposed |
| Bombay High Court | Court case (MCA) | Filed against the company by Deccan Queen Transport Company, THR. Its Aut. Attorney, Gajanan Uske., | Disposed |
To see the full case history of Sandu Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Sandu Pharmaceuticals Limited has 13 MSME Form 1 returns on record between 2019 and 2024, listing 690 overdue payments to 33 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 33)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Goa Paper and Board Converters Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Uts Express Cargo Private Limited |
To see the full MSME payment records of Sandu Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Sandu Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Sandu Phytoceuticals Private Limited | U24230GA2022PTC015422 |
To see the full group structure of Sandu Pharmaceuticals Limited, buy the company report.
Employees & EPFO
Sandu Pharmaceuticals Limited has a workforce of 295 employees on its EPFO records as of Mar 31, 2024, across 3 active EPFO establishments.
Employee count
295
Active EPFO establishments
3
Employee growth
-6.35%
GST
Sandu Pharmaceuticals has 6 GST registrations: 5 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
6
Active
5
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 30AAACS6291G1ZK | Goa | Active | 01 Jul 2017 |
| 08AAACS6291G1Z7 | Rajasthan | Active | 01 Jul 2017 |
| 23AAACS6291G1ZF | Madhya Pradesh | Active | 01 Jul 2017 |
| 24AAACS6291G1ZD | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Sandu Pharmaceuticals Limited, buy the company report.
Recent activity
Sandu Pharmaceuticals Limited has 18 board changes on record since 1992: 12 appointments and 6 cessations. The latest: Shubhada Prabhakar Sandu ceased to be Director on 13 Feb 2025.
Filing
Sandu Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Goa.
AGM
Sandu Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Shubhada Prabhakar Sandu ceased to be Director.
Appointed
Jayshree Bhasker Sandu was appointed as Director.
Appointed
Vijay Kottapalli was appointed as Director.
Ceased
Dilip Salgaocar Ramacrisna ceased to be Director.
Ceased
Kottapalli Vinay Kumar ceased to be Director.
Ceased
Krishna B Deshpande ceased to be Director.
Ceased
Madan Laxman Kapre ceased to be Director.
Appointed
Ajit Rajaram Kantak was appointed as Director.
Appointed
Balram Viswanathan was appointed as Director.
Charges
A charge registered on 09 Jul 2021 via Charge ID 100461391 with Hdfc Bank Limited was fully satisfied on 17 Jan 2022.
33 earlier events are in the company report.
News
Frequently asked questions
Sandu Pharmaceuticals is an active public limited company based in Goa, India. The company works in ayurvedic products and services, within the healthcare industry. It was incorporated on 15 November 1985 (41+ years old) and is registered under CIN L24233GA1985PLC001587. Listed on BSE: 524703.
Sandu Pharmaceuticals reported revenue of ₹69.93 Cr for FY 2025-26 (up 4.1% YoY) based on standalone financials.
Sandu Pharmaceuticals has 5 current directors:
- Shashank Bhaskar Sandu - Director
- Jayshree Bhasker Sandu - Director
- Vijay Kottapalli - Director
- Balram Viswanathan - Director
- Ajit Rajaram Kantak - Director
The latest financial statements of Sandu Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Sandu Pharmaceuticals is 30AAACS6291G1ZK, registered in Goa. The company has 6 GST registrations in all, of which 5 are active and 1 is cancelled or inactive. Other active GSTINs include 08AAACS6291G1Z7 (Rajasthan), 23AAACS6291G1ZF (Madhya Pradesh), 24AAACS6291G1ZD (Gujarat).
The CIN (Corporate Identification Number) of Sandu Pharmaceuticals is L24233GA1985PLC001587. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Sandu Pharmaceuticals is a listed company as per MCA records. Its shares are listed on BSE (code: 524703).
Sandu Pharmaceuticals has 26 court cases on record: 3 filed by the company and 23 filed against it. Most are in the district courts.
Sandu Pharmaceuticals was incorporated on 15 November 1985, making it 41+ years old. It is registered with the Registrar of Companies, Goa.
Sandu Pharmaceuticals has 18 deals on record (17 market trades, 1 funding round), with disclosed funding of ₹1.84 Cr; the latest was in March 2024.
The peers of Sandu Pharmaceuticals by revenue are Prakruti Products Private Limited, Kumaon Exports Private Limited, KRM Ayurveda Limited, Satyadivis Pharmaceuticals Private Limited, Africure Pharmaceuticals (India) Private Limited and 2 more, all in the Healthcare industry (Ayurvedic Products and Services, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Shubhada Prabhakar Sandu ceased to be Director on 13 Feb 2025. Jayshree Bhasker Sandu was appointed as Director on 30 Sep 2024. Vijay Kottapalli was appointed as Director on 12 Aug 2024. Sandu Pharmaceuticals has 18 board changes on record in total.